Recordati is a European pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, it has operations in the Czech Republic and Slovakia, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Russia and other C.I.S. countries, Spain, Turkey and the United Kingdom. Recordati has been listed on the Italian Stock Exchange since 1984.

Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases. A field force of around 1400 medical representatives promotes these products in all countries where subsidiaries have been established. The company's leading product is Zanidip® (lercanidipine), a latest generation calcium channel blocker for the treatment of hypertension discovered and entirely developed by Recordati which was followed more recently by Zanipress® (lercanidipine+enalapril). Two new products are currently being launched on the European market: Urorec® (silodosin) for the treatment of benign prostatic hyperplasia and Livazo® (pitavastatin) a latest generation cholesterol lowering agent. Recordati sells its proprietary pharmaceuticals directly to the market in the countries where it is present and through licensees elsewhere. Pharmaceutical production is based mainly in Italy (Milan) and France (Montluçon). Plants for the production of proprietary active ingredients are situated in Italy (Campoverde, Latina) and in Cork (Ireland).

Pharmaceutical research is focused on the discovery of new chemical entities for the treatment of urogenital conditions while development activities are concentrated on urology, on the area of rare diseases and on the cardiovascular therapeutic area, in particular on the further development of lercanidipine based products.

Recordati also has a minor pharmaceutical chemicals business. Recordati produces active ingredients for both its own proprietary pharmaceuticals and for the generic drugs industry. Over 90% of third party production is for the export markets.

Key consolidated data

• Consolidated revenue for 2010 is € 728.1 million. 
• Operating income for 2010 is € 154.8 million.
• Net income for 2010 is € 108.6 million.

Strategy

• Continue its commitment to research and development mainly in the urological and cardiovascular areas and in treatments for rare diseases. Special care is a priority in the development of the product pipeline.
• Expand through organic development and through acquisitions.
• Pursue geographical expansion by entering new markets characterized by high growth.
• Develop sales of orphan drugs in the U.S.A.